#1 Clinical Trials Search in Europe

Methoxy Polyethylene Glycol-Epoetin Beta

This article explores the use of Methoxy Polyethylene Glycol-Epoetin Beta, also known as Mircera or C.E.R.A., in clinical trials for treating anemia in patients with chronic kidney disease. These trials have investigated the drug’s effectiveness in maintaining hemoglobin levels, its dosing requirements, and its safety profile in both dialysis and non-dialysis patients.

Table of Contents

What is Methoxy Polyethylene Glycol-Epoetin Beta (Mircera)?

Methoxy polyethylene glycol-epoetin beta, commonly known as Mircera, is a medication used to treat anemia in patients with chronic kidney disease (CKD)[1]. It is also referred to as C.E.R.A. (Continuous Erythropoietin Receptor Activator)[2]. Mircera is a long-acting form of erythropoietin, a hormone that stimulates the production of red blood cells in your body[3].

What Conditions Does Mircera Treat?

Mircera is primarily used to treat:

  • Chronic Kidney Disease (CKD)-related anemia: This is the main condition for which Mircera is prescribed. It can be used in patients who are not on dialysis, as well as those undergoing dialysis treatment[1][2].
  • Renal anemia: This is a type of anemia specifically associated with kidney disease[4].

Anemia is a condition where you don’t have enough healthy red blood cells to carry adequate oxygen to your body’s tissues. In CKD patients, the kidneys may not produce enough erythropoietin, leading to anemia.

How Does Mircera Work?

Mircera works by stimulating the production of red blood cells in your body. It acts as a continuous erythropoietin receptor activator, which means it mimics the action of the natural hormone erythropoietin[2]. This helps increase and maintain your hemoglobin levels. Hemoglobin is the protein in red blood cells that carries oxygen throughout your body[3].

How is Mircera Administered?

Mircera is typically administered in the following ways:

  • Subcutaneous injection: This means the medication is injected just under the skin[2].
  • Monthly dosing: One of the advantages of Mircera is that it can often be given once a month, which is less frequent than some other anemia medications[5].

The specific administration schedule will be determined by your healthcare provider based on your individual needs and response to the treatment.

Dosage and Adjustments

The dosage of Mircera can vary depending on several factors:

  • Initial dosing: For patients starting Mircera treatment, the initial dose is often based on body weight. A common starting dose is 1.2 micrograms per kilogram of body weight[3].
  • Maintenance dosing: Once your hemoglobin levels stabilize, your doctor may adjust the dose to maintain your hemoglobin within a target range[5].
  • Dose adjustments: Your doctor may need to adjust your dose based on your hemoglobin levels, how you respond to the treatment, and any side effects you may experience[6].

It’s important to follow your doctor’s instructions carefully and attend all scheduled appointments for blood tests to monitor your hemoglobin levels.

Effectiveness of Mircera

Clinical studies have shown that Mircera is effective in treating anemia in CKD patients. Here are some key findings:

  • Hemoglobin maintenance: Many patients are able to maintain their hemoglobin levels within the target range (usually 10-12 g/dL) with monthly Mircera injections[5].
  • Long-term effectiveness: Studies have shown that Mircera can effectively maintain hemoglobin levels for extended periods, up to 36 months in some cases[6].
  • Reduced need for blood transfusions: By effectively treating anemia, Mircera can reduce the need for blood transfusions in some patients[5].

Safety and Side Effects

Like all medications, Mircera can cause side effects. Common side effects may include:

  • High blood pressure
  • Headache
  • Diarrhea
  • Inflammation of the nose and throat

Your doctor will monitor you closely for any adverse effects. It’s important to report any unusual symptoms or side effects to your healthcare provider[2].

Special Considerations

There are a few special considerations to keep in mind with Mircera treatment:

  • Iron supplementation: Your doctor may recommend iron supplements along with Mircera, as adequate iron levels are necessary for the medication to work effectively[6].
  • Altitude effects: The dose requirements of Mircera may be affected by altitude. Patients living at high altitudes may need different dosages[7].
  • Monitoring: Regular blood tests are necessary to monitor your hemoglobin levels and adjust your Mircera dose as needed[5].

Remember, Mircera is a prescription medication that should only be used under the guidance of a healthcare professional. Always follow your doctor’s instructions and report any concerns or side effects promptly.

Aspect Details
Drug Name Methoxy Polyethylene Glycol-Epoetin Beta (Mircera, C.E.R.A.)
Primary Use Treatment of anemia in chronic kidney disease patients
Administration Subcutaneous injection, typically once monthly
Target Hemoglobin 10-12 g/dL (some trials specify 11-12 g/dL)
Patient Types Pre-dialysis and dialysis patients (including peritoneal dialysis)
Trial Durations Typically 6-12 months, some up to 48 weeks or longer
Key Outcomes Hemoglobin maintenance, dose requirements, safety profile
Special Considerations Effects of altitude, inflammation markers (CRP, IL-6)

FAQ

  • What is Methoxy Polyethylene Glycol-Epoetin Beta used for? Methoxy Polyethylene Glycol-Epoetin Beta is used to treat anemia in patients with chronic kidney disease, both for those on dialysis and those not yet on dialysis. It helps maintain hemoglobin levels in the blood.
  • How is Methoxy Polyethylene Glycol-Epoetin Beta administered? The drug is typically administered subcutaneously (under the skin) once a month. The dosage is adjusted based on the patient's hemoglobin levels and previous treatments.
  • What are the target hemoglobin levels in these clinical trials? Most trials aimed to maintain hemoglobin levels between 10 and 12 grams per deciliter (g/dL), with some studies specifically targeting 11-12 g/dL.
  • Are there any side effects or risks associated with Methoxy Polyethylene Glycol-Epoetin Beta? While specific side effects weren't detailed in the provided information, the trials monitored for adverse events and serious adverse events. The safety profile was part of the evaluation in these studies.
  • How long do the clinical trials for this drug typically last? The duration of the trials varied, but many lasted between 6 to 12 months, with some extending up to 48 weeks or longer to assess long-term efficacy and safety.

Ongoing Clinical Trials on Methoxy Polyethylene Glycol-Epoetin Beta

  • Study on Roxadustat for Treating Anemia in Children with Chronic Kidney Disease

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Denmark Finland +14

Glossary

  • Anemia: A condition where there aren't enough healthy red blood cells to carry adequate oxygen to the body's tissues, often causing fatigue and weakness.
  • Chronic Kidney Disease (CKD): A long-term condition characterized by gradual loss of kidney function over time.
  • Dialysis: A treatment that filters and purifies the blood using a machine, taking over the function of the kidneys when they fail.
  • Erythropoiesis-Stimulating Agent (ESA): A type of drug that stimulates the production of red blood cells, used to treat anemia.
  • Hemoglobin (Hb): A protein in red blood cells that carries oxygen throughout the body. It's measured to assess anemia.
  • Subcutaneous (SC): A method of drug administration where the medication is injected just under the skin.
  • Efficacy Evaluation Period (EEP): A specific timeframe during a clinical trial when the effectiveness of the treatment is assessed.
  • Micrograms per kilogram (mcg/kg): A unit of measurement for drug dosage based on the patient's body weight.
  • C-reactive protein (CRP): A protein made by the liver that increases when there's inflammation in the body.
  • Interleukin-6 (IL-6): A protein involved in immune responses and a marker of inflammation.

References

  1. https://clinicaltrials.gov/study/NCT02238080
  2. https://clinicaltrials.gov/study/NCT00642967
  3. https://clinicaltrials.gov/study/NCT00462384
  4. https://clinicaltrials.gov/study/NCT01756612
  5. https://clinicaltrials.gov/study/NCT00737477
  6. https://clinicaltrials.gov/study/NCT02547454
  7. https://clinicaltrials.gov/study/NCT01519947